Search Clinical Trials

Clinical Trials Search Results

The results of your search are listed below. To view the details of a trial or study, click on the see details >> link. Or start a new search.

Searched for: Leukemia

64 results total

Allogeneic Nonmyeloablative Hematopoietic Stem Cell Transplant for Patients with BCR-ABL Tyrosine Kinase Inhibitor Responsive Ph+ Acute Leukemia ? a Multi-Center Trial

See details >>

Principal Investigator: George Georges, MD

Study Number: 1581.00

A Feasibility Trial Combining Radiolabeled BC8 (Anti-CD45) Antibody with Fludarabine and Low Dose TBI Followed by Related or Unrelated PBSC Infusion and Post-Transplant Immunosuppression for Patients with Advanced AML or High Risk Myelodysplastic Syndrome

See details >>

Principal Investigator: John Pagel, MD, PhD

Study Number: 1809.00

Nonmyeloablative Conditioning with Pre- and Post-Transplant Rituximab followed by Related or Unrelated Donor Hematopoietic Cell Transplantation for Patients with Advanced Chronic Lymphocytic Leukemia: A Multi-Center Trial

See details >>

Principal Investigator: Mohamed Sorror, MD, MSc

Study Number: 1840.00

Low-dose TBI Dose Escalation to Decrease Risks of Progression and Graft Rejection after Hematopoietic Cell Transplantation with Nonmyeloablative Conditioning as Treatment for Untreated Myelodysplastic Syndrome or Myeloproliferative Disorders -- A Multi-Center Trial

See details >>

Principal Investigator: Brenda Sandmaier, MD

Study Number: 2056.00

Nonmyeloablative Hematopoietic Cell Transplantation for Patients with Fanconi Anemia Using Alternative Marrow Donors: A Phase I/II Dose-Finding Study

See details >>

Principal Investigator: Monica Thakar, MD

Study Number: 2064.00

Cyclophosphamide Followed by Intravenous Busulfan as Conditioning for Hematopoietic Cell Transplantation in Patients with Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome.

See details >>

Principal Investigator: Andrew Rezvani, MD

Study Number: 2130.00

Phase II Trial of Vorinostat (Suberoylanilide Hydroxamic Acid or SAHA; Zolinza?) in Combination with Gemtuzumab Ozogamicin (Mylotarg?) as Induction and Post-Remission Therapy in Older Patients with Previously Untreated Non-M3 Acute Myeloid Leukemia

See details >>

Principal Investigator: Roland Walter, MD

Study Number: 2200.00

A Multi-center Phase II Study of Selective Depletion of CD45RA+ T cells from Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD

See details >>

Principal Investigator: Marie Bleakley, MD

Study Number: 2222.00

Conditioning With Treosulfan, Fludarabine And Escalating Doses of TBI for Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

See details >>

Principal Investigator: Merav Bar, MD

Study Number: 2272.00

A Phase II Study of Fludarabine (F), Rituximab (R) and Avastin (A) Followed by RA Maintenance Therapy in Patients with Relapsed/Refractory B-cell Chronic Lymphocytic Leukemia (CLL)

See details >>

Principal Investigator: John Pagel, MD, PhD

Study Number: 2278.00

Displaying first 10 of 64 total results. Click to view all 64 results.

Search Options

Select a disease from the list below:

Limit results to studies enrolling:
Both Adults & Pediatrics Adults Pediatrics

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

Talk to your health care providers first before making decisions about your health care.
Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Fred Hutchinson Cancer Research Center
1100 Fairview Ave. N. PO Box 19024 Seattle, WA 98109
©2009 Fred Hutchinson Cancer Research Center, a nonprofit organization.
Terms of Use & Privacy Policy.